


This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended): A compound of Formula I ~~Formulas I, II, III, or IV~~:



wherein

- A is an indazolyl, ~~benzothiazolyl, or isobenzothiazolyl~~ group according to subformula (a) ~~subformulas (a) to (c), respectively~~,



X is O or S;

R¹ is H, F, Cl, Br, I, OH, CN, nitro, NH₂, alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, cycloalkylalkoxy having 4 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;

R² is H, alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, or cycloalkylalkyl having 4 to 7 carbon atoms;

~~R³ is H, F, Cl, Br, I, OH, CN, nitro, NH₂, alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, cycloalkylalkoxy having 4 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;~~

~~R⁴ is H, F, Cl, Br, I, OH, CN, nitro, NH₂, alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, cycloalkylalkoxy having 4 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group~~

independently has 1 to 4 carbon atoms, Ar or Het;

R^5 — is H, F, Cl, Br, I, OH, CN, nitro, NH_2 , alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, cycloalkylalkoxy having 4 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;

Ar is an aryl group containing 6 to 10 carbon atoms which is unsubstituted or substituted one or more times by alkyl having 1 to 8 carbon C atoms, alkoxy having 1 to 8 carbon C atoms, halogen, dialkylamino wherein the alkyl portions each have 1 to 8 carbon C atoms, amino, cyano, hydroxyl, nitro, halogenated alkyl having 1 to 8 carbon C atoms, halogenated alkoxy having 1 to 8 carbon C atoms, hydroxyalkyl having 1 to 8 carbon C atoms, hydroxyalkoxy having 2 to 8 carbon C atoms, alkenyloxy having 3 to 8 carbon C atoms, alkylthio having 1 to 8 carbon C atoms, alkylsulphinyl having 1 to 8 carbon C atoms, alkylsulphonyl having 1 to 8 carbon C atoms, monoalkylamino having 1 to 8 carbon C atoms, cycloalkylamino wherein the cycloalkyl group has 3 to 7 carbon C atoms and is optionally substituted, aryloxy wherein the aryl portion contains 6 to 10 carbon atoms and is optionally substituted, arylthio wherein the aryl portion contains 6 to 10 carbon atoms and is optionally substituted, cycloalkyloxy wherein the cycloalkyl group has 3 to 7 carbon C atoms and is optionally substituted, sulfo, sulfonylamino, acylamido, acyloxy or combinations thereof; and

Het is a heterocyclic group, which is fully saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl having 6 to 10

MEMORY-33




carbon atoms and is optionally substituted, alkyl having 1 to 8 carbon \in atoms, alkoxy having 1 to 8 carbon \in atoms, cyano, trifluoromethyl, nitro, oxo, amino, monoalkylamino having 1 to 8 carbon \in atoms, dialkylamino wherein each alkyl group has 1 to 8 carbon \in atoms, or combinations thereof; or


a pharmaceutically acceptable salt thereof,

wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer, and

~~wherein when said compound is of Formula I the indazolyl group of group A is attached via its 3, 4, or 7 position, the benzothiazolyl group of group A is attached via its 4 or 7 position, or the isobenzothiazolyl group of group A is attached via its 3, 4, or 7 position.~~


2. (Currently Amended): A compound according to claim 1, wherein said compound is of formulas Ia, Ib, or ~~Ie, If, Ii, Ij, Ik, or Ie~~:







wherein X is O.

3. (Cancelled):
4. (Cancelled):
5. (Cancelled):
6. (Currently Amended): A compound according to Formula I' Formulae I'-IV':



wherein

A is an indazolyl or benzothiazolyl according to subformula (a) ~~subformulas (a) to (b)~~, respectively,



R^1 is H, F, Cl, Br, I, OH, CN, nitro, NH_2 , alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;

R^2 is H, alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, or cycloalkylalkyl having 4 to 7 carbon atoms;

MEMORY-33

R^3 — is H, F, Cl, Br, I, OH, CN, nitro, NH_2 , ~~alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;~~

Ar is an aryl group containing 6 to 10 carbon atoms which is unsubstituted or substituted one or more times by alkyl having 1 to 8 carbon C atoms, alkoxy having 1 to 8 carbon C atoms, halogen, dialkylamino wherein the alkyl portions each have 1 to 8 carbon C atoms, amino, cyano, hydroxyl, nitro, halogenated alkyl having 1 to 8 carbon C atoms, halogenated alkoxy having 1 to 8 carbon C atoms, hydroxyalkyl having 1 to 8 carbon C atoms, hydroxyalkoxy having 2 to 8 carbon C atoms, alkenyloxy having 3 to 8 carbon C atoms, alkylthio having 1 to 8 carbon C atoms, alkylsulphinyl having 1 to 8 carbon C atoms, alkylsulphonyl having 1 to 8 carbon C atoms, monoalkylamino having 1 to 8 carbon C atoms, cycloalkylamino wherein the cycloalkyl group has 3 to 7 carbon C atoms and is optionally substituted, aryloxy wherein the aryl portion contains 6 to 10 carbon atoms and is optionally substituted, arylthio wherein the aryl portion contains 6 to 10 carbon atoms and is optionally substituted, cycloalkyloxy wherein the cycloalkyl group has 3 to 7 carbon C atoms and is optionally substituted, sulfo, sulfonylamino, acylamido, acyloxy or combinations thereof; and

Het is a heterocyclic group, which is fully saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl




having 6 to 10 carbon atoms and is optionally substituted, alkyl having 1 to 8 carbon \in atoms, alkoxy having 1 to 8 carbon \in atoms, cyano, trifluoromethyl, nitro, oxo, amino, monoalkylamino having 1 to 8 carbon \in atoms, dialkylamino wherein each alkyl group has 1 to 8 carbon \in atoms, or combinations thereof; or


a pharmaceutically acceptable salt thereof,

wherein if the compound exhibits chirality it can be in the form of a mixture of enantiomers such as a racemate or a mixture of diastereomers, or can be in the form of a single enantiomer or a single diastereomer, and

wherein the indazolyl group of subformula (a) is attached to the remainder of the compound via its 3, 4 or 7 position.

7. (Currently Amended): A compound according to claim 6, wherein said compound is of formula I'a, I'b or I'e ~~Ib, Ie, If, or Ii~~:





8. (Cancelled):
9. (Cancelled):
10. (Cancelled):
11. (Previously Presented): A compound according to claim 1, wherein R^1 is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl.
12. (Previously Presented): A compound according to claim 1, wherein R^2 is H, methyl, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl.
13. (Cancelled):
14. (Previously Presented): A compound according to claim 1, wherein R^1 is H, F, Cl, Br, methyl, methoxy, or amino.
15. (Previously Presented): A compound according to claim 1, wherein R^2 is H or methyl.

16. (Cancelled):

17. (Cancelled):

18. (Cancelled):

19. (Currently Amended): A compound according to claim 147, wherein R¹ is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl, and R² is H, methyl, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl, ~~and R³ is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl.~~

20. (Cancelled):

21. (Currently Amended) A compound according to claim 1, wherein said compound is selected from:

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)benzo[d]isothiazole-3-carboxamide,~~
N-(1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide,
N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide,
N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide,
1-Methyl-1H-Indazole-3-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,
(R) 1-Methyl-1H-Indazole-3-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,
(S) 1-Methyl-1H-Indazole-3-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(methoxy)benzo[d]isothiazole-3-carboxamide,~~
N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)-1H-indazole-3-carboxamide,
N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(cyclopropyl)-1H-indazole-3-carboxamide,
N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1H-indazole-3-carboxamide,
N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1H-indazole-3-carboxamide,
N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide,

MEMORY-33

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-methoxybenzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1H-indazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-bromobenzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-cyclopropylbenzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(2-fluorophenyl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-fluorophenyl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(4-fluorophenyl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-furan-3-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-methoxybenzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(morpholin-4-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-phenylbenzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-3-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-4-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(bromo)-1H-indazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)-1H-indazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(phenyl)-1H-indazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)-1H-indazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-bromobenzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-cyclopropylbenzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(2-fluorophenyl)benzo[d]isothiazole-3-carboxamide,~~

MEMORY-33

~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-fluorophenyl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(4-fluorophenyl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-methoxybenzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(morpholin-4-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-phenylbenzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-3-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-4-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)benzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(bromo)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(phenyl)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)-1H-indazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)-1H-indazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-7-methoxybenzo[d]isothiazole-3-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-7-methoxybenzo[d]isothiazole-3-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-N-(1H-indazol-3-ylmethyl)amine,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-N-(1H-indazol-3-ylmethyl)amine,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)benzothiazole-4-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)benzothiazole-4-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-4-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-4-carboxamide,~~
~~N-(1H-Indazol-4-yl)-1-azabicyclo[2.2.2]oct-3-ylcarboxamide,~~
~~N-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(1H-indazol-4-ylmethyl)amine,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)benzothiazole-7-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)benzothiazole-7-carboxamide,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide,~~

N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide,
~~Benzothiazole-4-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,~~
~~(R)-Benzothiazole-4-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,~~
~~(S)-Benzothiazole-4-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,~~
 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-3-yl,
 (S) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-3-yl,
 (R) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-3-yl,
 (S) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-4-yl,
 (R) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-4-yl,
 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-7-yl,
 (S) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-7-yl,
 (R) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-7-yl,
~~1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-4-yl,~~
~~(S)-1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-4-yl,~~
~~(R)-1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-4-yl,~~
~~1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-7-yl,~~
~~(S)-1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-7-yl,~~
~~(R)-1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-7-yl,~~
~~(S)-(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-3-ylmethyl)-amine,~~
~~(R)-(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-3-ylmethyl)-amine,~~
~~(S)-(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-4-ylmethyl)-amine,~~
~~(R)-(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-4-ylmethyl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-5-ylmethyl)-amine,~~
~~(S)-(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-5-ylmethyl)-amine,~~
~~(R)-(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-5-ylmethyl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-6-ylmethyl)-amine,~~
~~(S)-(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-6-ylmethyl)-amine,~~
~~(R)-(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-6-ylmethyl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-7-ylmethyl)-amine,~~

~~(S) (1-Aza-bicyclo[2,2,2]oct-3-yl) (1H-indazol-7-ylmethyl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-yl) (1H-indazol-7-ylmethyl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-4-ylmethyl)-amine,—~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-4-ylmethyl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-4-ylmethyl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-5-ylmethyl)-amine,~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-5-ylmethyl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-5-ylmethyl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-6-ylmethyl)-amine,~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-6-ylmethyl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-6-ylmethyl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-7-ylmethyl)-amine,~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-7-ylmethyl)-amine,—~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-yl) (benzothiazol-7-ylmethyl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-3-yl)-amine,~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-3-yl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-3-yl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-4-yl)-amine,~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-4-yl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-4-yl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-5-yl)-amine,~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-5-yl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-5-yl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-6-yl)-amine,~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-6-yl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-6-yl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-7-yl)-amine,~~
~~(S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-7-yl)-amine,~~
~~(R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl) (1H-indazol-7-yl)-amine,~~

~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-4-yl)-amine,~~
~~(S)-(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-4-yl)-amine,~~
~~(R)-(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-4-yl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-5-yl)-amine,~~
~~(S)-(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-5-yl)-amine,~~
~~(R)-(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-5-yl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-6-yl)-amine,~~
~~(S)-(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-6-yl)-amine,~~
~~(R)-(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-6-yl)-amine,~~
~~(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-7-yl)-amine,~~
~~(S)-(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-7-yl)-amine,~~
~~(R)-(1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-7-yl)-amine,~~
and pharmaceutically acceptable physiological salts thereof.

22. (Previously Presented): A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

23. (Currently Amended): A method of selectively activating/stimulating α -7 nicotinic receptors in a mammal wherein such activation/stimulation has a therapeutic effect, comprising administering to a mammal ~~an animal~~ in need thereof an effective amount of a compound according to claim 1.

24. (Previously Presented): A method of treating a patient suffering from psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system, and conditions of memory and/or cognition impairment comprising administering to the patient an effective amount of a compound according to claim 1.

25. (Previously Presented): A method of treating a patient suffering from dementia and other conditions with memory loss comprising administering to the patient an effective

amount of a compound according to claim 1.

26. (Currently Amended): A method of treating a patient suffering from memory impairment due to mild cognitive impairment due to aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob ~~Creutzfeld-Jakob~~ disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, or multiinfarct dementia comprising administering an effective amount of a compound according ~~aeording~~ to claim 1.

27. (Previously Presented): A method of treating and/or preventing dementia in an Alzheimer's patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 to inhibit the binding of an amyloid beta peptide with nAChRs.

28. (Previously Presented): A method of treating a patient for alcohol withdrawal or treating a patient with anti-intoxication therapy comprising administering to the patient an effective amount of a compound according to claim 1.

29. (Previously Presented): A method of treating a patient to provide for neuroprotection against damage associated with strokes and ischemia and glutamate-induced excitotoxicity comprising administering to the patient an effective amount of a compound according to claim 1.

30. (Previously Presented): A method of treating a patient suffering from nicotine addiction, pain, jetlag, obesity and/or diabetes, or a method of inducing smoking cessation in a patient comprising administering to the patient an effective amount of a compound according to claim 1.

31. (Previously Presented): A method of treating a patient suffering from mild
MEMORY-33

cognitive impairment (MCI), vascular dementia (VaD), age-associated cognitive decline (AACD), amnesia associated with open-heart-surgery, cardiac arrest, general anesthesia, memory deficits from exposure to anesthetic agents, sleep deprivation induced cognitive impairment, chronic fatigue syndrome, narcolepsy, AIDS-related dementia, epilepsy-related cognitive impairment, Down's syndrome, Alcoholism related dementia, drug/substance induced memory impairments, Dementia Puglistica (Boxer Syndrome), or animal dementia comprising administering to the patient an effective amount of a compound according to claim 1.

32. (Previously Presented): A method of treating a patient suffering from a disease state involving decreased nicotinic acetylcholine receptor activity comprising administering to the patient an effective amount of a compound according to claim 1.

33. (Previously Presented): A method for the treatment or prophylaxis of a disease or condition resulting from dysfunction of nicotinic acetylcholine receptor transmission in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1.

34. (Previously Presented): A method for the treatment or prophylaxis of a disease or condition resulting from defective or malfunctioning nicotinic acetylcholine receptors in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1.

35. (Previously Presented): A method for the treatment or prophylaxis of a disease or condition resulting from suppressed nicotinic acetylcholine receptor transmission in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1.

36. (Previously Presented): A method for the treatment or prophylaxis of a disease or condition resulting from loss of cholinergic synapses in a mammal comprising administering to

the mammal an effective amount of a compound according to claim 1.

37. (Previously Presented): A method of treating a patient suffering from inflammation comprising administering to the patient an effective amount of a compound according to claim 1.

38. (Previously Presented): A compound according to claim 21, wherein said compound is in the form of a hydrochloride or hydroformate salt.

39. (Currently Amended): A compound according to claim 38, wherein said compound is selected from:

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)benzo[d]isothiazole-3-carboxamide hydrochloride,~~

~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)benzo[d]isothiazole-3-carboxamide hydrochloride,~~

~~N-(-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide hydrochloride,~~

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide hydrochloride,~~

~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide hydrochloride,~~

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(methoxy)benzo[d]isothiazole-3-carboxamide hydroformate,~~

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(cyclopropyl)-1H-indazole-3-carboxamide hydroformate,~~

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1H-indazole-3-carboxamide hydroformate,~~

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1H-indazole-3-carboxamide hydroformate,~~

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide hydroformate,~~

~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1H-indazole-3-carboxamide hydroformate,~~

~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-methoxybenzo[d]isothiazole-3-carboxamide hydroformate,~~

~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1H-indazole-3-carboxamide hydroformate,~~

~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1H-indazole-3-carboxamide hydroformate,~~

MEMORY-33

~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(2-fluorophenyl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-fluorophenyl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(4-fluorophenyl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-furan-3-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(morpholin-4-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-phenylbenzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-3-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-4-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(phenyl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(2-fluorophenyl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-fluorophenyl)benzo[d]isothiazole-3-carboxamide hydroformate,~~

~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(4-fluorophenyl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(morpholin-4-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-phenylbenzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-3-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-4-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)benzo[d]isothiazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(phenyl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)-1H-indazole-3-carboxamide hydroformate,~~
~~N-((3R)-1-Aza-bicyclo[2.2.2]oct-3-yl)benzothiazole-4-carboxamide dihydrochloride,~~
~~N-((3S)-1-Aza-bicyclo[2.2.2]oct-3-yl)benzothiazole-4-carboxamide dihydrochloride,~~
~~N-((3R)-1-Azabicyclo[2,2,2]oct-3-yl)benzothiazole-7-carboxamide hydrochloride,~~
~~N-((3S)-1-Azabicyclo[2,2,2]oct-3-yl)benzothiazole-7-carboxamide hydrochloride,~~
~~N-((3R)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide hydrochloride, and~~
~~N-((3S)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide hydrochloride.~~

40. (Cancelled):

41. (Cancelled):

42. (Cancelled):
43. (Cancelled):
44. (Cancelled):
45. (Cancelled):
46. (Cancelled):
47. (Cancelled):
48. (New): A compound according to claim 21, wherein said compound is N-(1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.
49. (New): A compound according to claim 48, wherein said compound is N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.
50. (New): A compound according to claim 48, wherein said compound is N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.
51. (New): A compound according to claim 21, wherein said compound is N-(1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

52. (New): A compound according to claim 51, wherein said compound is N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

53. (New): A compound according to claim 51, wherein said compound is N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

54. (New): A compound according to claim 21, wherein said compound is N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(cyclopropyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

55. (New): A compound according to claim 21, wherein said compound is N-(1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

56. (New): A compound according to claim 55, wherein said compound is N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

57. (New): A compound according to claim 55, wherein said compound is N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

58. (New): A compound according to claim 21, wherein said compound is N-(1-Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

59. (New): A compound according to claim 58, wherein said compound is N-((3*R*)-1-

MEMORY-33

Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

60. (New): A compound according to claim 58, wherein said compound is N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

61. (New): A compound according to claim 21, wherein said compound is N-(1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

62. (New): A compound according to claim 61, wherein said compound is N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

63. (New): A compound according to claim 61, wherein said compound is N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

64. (New): A compound according to claim 21, wherein said compound is N-(1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

65. (New): A compound according to claim 64, wherein said compound is N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

66. (New): A compound according to claim 64, wherein said compound is N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1H-indazole-3-carboxamide or a pharmaceutically acceptable salt thereof.

MEMORY-33

acceptable salt thereof.